Metformin vs Tresiba (Insulin Degludec): Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Metformin and Tresiba occupy different positions in the type 2 diabetes treatment algorithm, yet patients and clinicians frequently weigh them against each other at a specific decision point: when oral therapy alone no longer keeps A1C below target. The comparison matters because the cost gap between the two is enormous, and insurance friction around basal insulin access can delay treatment intensification by months.

The American Diabetes Association's 2024 Standards of Care recommend metformin as first-line pharmacotherapy for most adults with type 2 diabetes. Basal insulin, including insulin degludec (brand name Tresiba), enters the algorithm when A1C remains above target despite dual or triple oral/injectable therapy, or when hyperglycemia is severe at diagnosis (A1C ≥10% or blood glucose ≥300 mg/dL). These are not interchangeable medications. They address different pathophysiologic mechanisms at different disease stages. Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity [1]. Tresiba provides exogenous basal insulin with an ultra-long duration of action exceeding 42 hours [2].

The clinical question is rarely "which one should I take" but rather "when do I need to add the second, and can I afford it?"

Retail Cost Comparison

Generic metformin is one of the least expensive prescription medications in the United States. Tresiba, still under patent protection, sits at the opposite end of the pricing spectrum.

A 30-day supply of metformin 500 mg twice daily costs between $4 and $30 at major retail pharmacies, including Walmart, Costco, and CVS [3]. The drug appears on nearly every $4 generic list in the country. Even the extended-release formulation (metformin ER) rarely exceeds $40 per month without insurance. According to GoodRx data and FDA Orange Book records, multiple manufacturers produce generic metformin, which keeps prices low through market competition.

Tresiba tells a different story. The wholesale acquisition cost (WAC) for a single 3 mL FlexTouch pen of Tresiba U-100 is approximately $533. Patients on moderate doses (30 to 50 units daily) may use one to two pens per month, placing the monthly list price between $533 and $1,066. Even the Tresiba U-200 concentration, designed to reduce injection volume, carries a comparable per-unit cost [4]. Novo Nordisk has introduced authorized biosimilar pathways and patient assistance, but the branded product remains expensive at the pharmacy counter.

The price ratio is staggering. A patient paying cash for metformin spends roughly $48 per year. The same patient paying list price for Tresiba could spend over $6,000 annually. This 125-fold cost difference shapes prescribing behavior, formulary placement, and patient adherence patterns across the U.S. healthcare system.

Insurance Coverage and Formulary Access

Metformin enjoys universal formulary coverage. Tresiba faces significant access barriers depending on the payer.

Every major commercial insurer, Medicare Part D plan, and state Medicaid program covers generic metformin at the lowest copay tier (Tier 1). No prior authorization is required. No step therapy applies. A patient can walk into a pharmacy with a new prescription and leave with medication the same day, typically paying $0 to $10 with insurance [5].

Tresiba access varies widely. Most commercial plans place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $50 to $150 per month after deductible. Many plans require prior authorization documenting failure of, or intolerance to, other basal insulins such as insulin glargine (Lantus, Basaglar) or insulin detemir (Levemir) before covering Tresiba [6]. Some Medicare Part D plans exclude Tresiba entirely from their formularies, directing patients toward biosimilar glargine products instead.

The Centers for Medicare & Medicaid Services classifies insulins as protected class drugs, meaning Part D plans must cover at least one product per formulation category. This does not guarantee Tresiba specifically will be covered. Patients enrolled in Medicare Part D should verify formulary placement during open enrollment each year.

Novo Nordisk offers a patient savings program for commercially insured patients, capping out-of-pocket Tresiba costs at $25 per fill for up to 24 months. Uninsured patients may qualify for the Novo Nordisk Patient Assistance Program (PAP), which provides Tresiba at no cost to those meeting income thresholds below 400% of the federal poverty level [7].

Clinical Efficacy: UKPDS 34 and DEVOTE

No head-to-head randomized trial has directly compared metformin to insulin degludec. The evidence base for each drug comes from separate landmark trials conducted decades apart in different patient populations.

UKPDS 34, published in The Lancet in 1998, randomized 1,704 overweight patients with newly diagnosed type 2 diabetes to intensive glucose control with metformin versus conventional dietary therapy. Over a median follow-up of 10.7 years, metformin produced a 32% risk reduction in any diabetes-related endpoint (P = 0.002), a 42% reduction in diabetes-related death (P = 0.017), and a 36% reduction in all-cause mortality (P = 0.011) [1]. No other glucose-lowering drug has matched these mortality data in a prospective randomized trial of type 2 diabetes. The UKPDS legacy effect, demonstrated in the 10-year post-trial follow-up published in 2008, showed that mortality benefits persisted even after between-group A1C differences disappeared [8].

DEVOTE, published in the New England Journal of Medicine in 2017, was a cardiovascular outcomes trial (CVOT) comparing insulin degludec to insulin glargine U-100 in 7,637 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint of major adverse cardiovascular events (MACE) occurred in 8.5% of the degludec group versus 9.3% of the glargine group (HR 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority) [2]. The degludec group experienced 53% fewer episodes of severe nocturnal hypoglycemia (rate ratio 0.47; P = 0.002) and 40% fewer overall severe hypoglycemic events (rate ratio 0.60; P<0.001) [2].

These trials answer different questions. UKPDS 34 established metformin as a drug that reduces death, not just blood sugar. DEVOTE showed that degludec is at least as safe as glargine from a cardiovascular standpoint and carries a meaningful hypoglycemia advantage. Neither trial tells us what happens when a patient switches directly from metformin to Tresiba, because that comparison was never studied in isolation.

When Clinicians Add Tresiba to Metformin

The ADA/EASD consensus algorithm does not frame this as an either/or decision. Most patients who start Tresiba continue taking metformin simultaneously.

According to the 2024 ADA Standards of Care, basal insulin should be considered when A1C remains above the individualized target (typically 7.0% for most adults) despite maximally tolerated metformin plus one or two additional agents such as SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors [5]. The guideline specifically recommends continuing metformin when adding basal insulin unless contraindications develop (eGFR <30 mL/min/1.73 m² or acute illness predisposing to lactic acidosis).

Dr. Irl Hirsch, professor of medicine at the University of Washington, has noted: "The combination of metformin plus basal insulin is one of the most cost-effective regimens in diabetes care. Metformin handles hepatic glucose output while basal insulin covers the deficit in endogenous secretion. Removing metformin when you add insulin typically worsens glycemic control and increases the insulin dose required."

Real-world prescribing data from the IQVIA National Prescription Audit shows that over 80% of patients prescribed basal insulin in the U.S. also fill concurrent metformin prescriptions. The drugs are complementary, not competitive.

The specific choice of Tresiba over other basal insulins (glargine, detemir) typically hinges on three factors: hypoglycemia risk, dosing flexibility, and formulary access. DEVOTE's hypoglycemia data favor degludec for patients with a history of severe hypoglycemia or those who work night shifts and need flexible injection timing (Tresiba allows a dosing window of 8 to 40 hours between injections without loss of glycemic control) [2].

Out-of-Pocket Strategies for Patients

Practical cost reduction depends on which drug creates the financial burden. For most patients, metformin costs are negligible; the real expense is insulin.

For metformin: Walmart's ReliOn pharmacy program and similar $4 generic lists cover immediate-release metformin. Extended-release formulations cost slightly more but remain under $40 per month. Patients with no insurance should request the generic specifically (avoid brand-name Glucophage, which can cost 10 to 20 times more). Mark Cuban's Cost Plus Drugs platform lists metformin at $3.60 for a 90-day supply of 500 mg tablets [9].

For Tresiba: The Novo Nordisk savings card reduces copays to $25 per month for commercially insured patients. Medicare beneficiaries cannot use manufacturer coupons but may benefit from the Part D Senior Savings Model, which caps insulin copays at $35 per month for participating plans (now permanent under the Inflation Reduction Act of 2022) [10]. Patients who do not qualify for any assistance program may ask their prescriber about therapeutic substitution to biosimilar glargine (Semglee, Rezvoglar), which typically carries lower copays and fewer prior authorization requirements.

State-level insulin price caps also affect access. As of 2025, more than 25 states have enacted laws capping insulin copays at $25 to $100 per 30-day supply, regardless of plan type [10]. Patients should check their state's specific statute, as some laws apply only to state-regulated plans and exclude self-funded employer plans governed by ERISA.

Safety and Side Effect Profiles

Metformin's most common side effects are gastrointestinal: nausea, diarrhea, and abdominal cramping, affecting 20% to 30% of patients at initiation. Slow dose titration (starting at 500 mg daily, increasing by 500 mg weekly) and using the extended-release formulation reduce GI intolerance to below 10% [11]. The rare but serious risk is lactic acidosis, which occurs at an estimated rate of 3 to 10 cases per 100,000 patient-years and is almost exclusively seen in patients with severe renal impairment or acute hemodynamic instability [11]. Metformin does not cause hypoglycemia when used as monotherapy. It is weight-neutral to mildly weight-reducing (mean weight loss of 1 to 2 kg in UKPDS 34) [1].

Tresiba's primary risk is hypoglycemia. In DEVOTE, severe hypoglycemia occurred in 4.9% of degludec-treated patients over 2 years, compared to 6.6% with glargine [2]. Weight gain is expected with any exogenous insulin; DEVOTE reported a mean weight increase of 2.8 kg over the trial period [2]. Injection-site reactions occur in approximately 2% of patients. Insulin degludec carries no risk of lactic acidosis and no GI side effects.

The safety trade-off is clear: metformin risks GI symptoms but not hypoglycemia; Tresiba risks hypoglycemia but not GI symptoms. When used together, patients face both risk categories but gain complementary glycemic control.

Who Should Consider Each Drug

The decision between metformin and Tresiba is almost never binary. It follows a staged treatment algorithm.

Start with metformin: newly diagnosed type 2 diabetes, A1C 6.5% to 9.0%, eGFR ≥30 mL/min/1.73 m², no contraindications. This applies to the vast majority of patients at diagnosis [5].

Add Tresiba (or another basal insulin) when: A1C remains above target despite metformin plus one or two additional agents, fasting glucose is consistently above 180 mg/dL, or the patient presents with A1C ≥10% and symptomatic hyperglycemia requiring immediate insulin [5]. Consider Tresiba specifically over other basal insulins when the patient has a history of nocturnal hypoglycemia, needs dosing flexibility due to irregular schedules, or has failed prior basal insulin therapy with glargine or detemir.

A small subset of patients diagnosed with type 2 diabetes require insulin from day one: those presenting in diabetic ketoacidosis (rare in type 2), those with very high A1C (≥10%), and those with latent autoimmune diabetes of adults (LADA) initially misclassified as type 2. For these patients, the question is not metformin versus insulin but rather insulin alone versus insulin plus metformin. The ADA recommends adding metformin to insulin whenever feasible to reduce insulin dose requirements and provide potential cardiovascular benefit [5].